



TECH CENTER 1600/2800

JUL 18 2002

RECEIVED

Page 1 of 10

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
RT	AA1	4,526,938	07/02/1985	Churchill et al.	525	415	04/15/1983
	AB1	4,654,324	03/31/1987	Chance et al.	514	12	12/17/1984
	AC1	4,853,226	08/01/1989	Machida et al.	424	426	10/07/1987
	AD1	4,857,505	08/15/1989	Arendt	514	2	03/09/1987
	AE1	4,942,035	07/17/1990	Churchill et al.	424	423	03/27/1985
	AF1	4,985,404	01/15/1991	Mitchell	514	6	06/29/1988
	AG1	B1 4,985,404	04/21/1992	Mitchell	514	6	06/29/1988
	AH1	5,091,185	02/25/1992	Castillo et al.	424	438	06/20/1990
	AI1	5,118,666	06/02/1992	Habener	514	12	06/01/1990
	AJ1	5,120,712	06/09/1992	Habener	514	12	06/01/1990
	AK1	5,156,851	10/20/1992	Castillo et al.	424	497	09/19/1991

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
RT	AL1	EP 0 092 918 A2	11/02/1983	Europe			Yes No
	AM1	EP 0 177 478 A2	04/09/1986	Europe			Yes No
	AN1	WO 87/06941 A1	11/19/1987	WIPO			Yes No
	AO1	EP 0 263 490 B1	04/13/1988	Europe			Yes No
	AP1	JP 63-91325	04/22/1988	Japan			Yes X/No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	1	Ballard, B.E., "Chapter 91: Prolonged-Action Pharmaceuticals," in <i>Remington's Pharmaceutical Sciences</i> , 16 th Edition, Osol, A. (ed.), Mack Printing Company, Easton, PA, pp. 1594-1613 (1980).
	AS	1	Bell, G.I. et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," <i>Nature</i> 302:716-718, Macmillan Journals Ltd. (1983).
	AT	1	Biessels, G.-J. et al., "Place Learning and Hippocampal Synaptic Plasticity in Streptozotocin-Induced Diabetic Rats," <i>Diabetes</i> 45: 1259-1266, The American Diabetes Association (September 1996).

EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1658.0020003/MAC/MBT

APPLICATION NO.
09/943,084

APPLICANT
KIM et al.

FILING DATE
August 31, 2001

GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
RT	AA2	5,175,145	12/29/1992	Cooper	514	4	01/14/1992
I	AB2	5,232,708	08/03/1993	Castillo et al.	424	497	05/21/1992
	AC2	5,424,286	06/13/1995	Eng	514	2	05/24/1993
	AD2	5,536,508	07/16/1996	Canal et al.	424	501	10/21/1993
	AE2	5,545,618	08/13/1996	Buckley et al.	514	12	12/10/1993
	AF2	5,574,008	11/12/1996	Johnson et al.	514	12	08/30/1994
	AG2	5,614,492	03/25/1997	Habener	514	12	11/23/1993
	AH2	5,631,224	05/20/1997	Efendic et al.	514	12	10/13/1994
I	AI2	5,700,486	12/23/1997	Canal et al.	424	501	04/30/1996
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
RT	AL2	WO 88/07366 A1	10/06/1988	WIPO			Yes No
I	AM2	EP 0 343 696 A2	11/29/1989	Europe			Yes No
	AN2	WO 90/11296 A1	10/04/1990	WIPO			Yes No
	AO2	WO 91/11457 A1	08/08/1991	WIPO			Yes No
I	AP2	EP 0 442 671 A2	08/21/1991	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	2	Blackmore, P.F. et al., "Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes," <i>FEBS</i> 283:7-10, Federation of European Biochemical Societies and Elsevier Science Publishers B.V. (1991).
I	AS	2	Cross, S.E. and Roberts, M.S., "Subcutaneous Absorption Kinetics and Local Tissue Distribution of Interferon and Other Solutes," <i>J. Pharm. Pharmacol.</i> 45:606-609, Pharmaceutical Press (July 1993).
I	AT	2	Deckert, T. et al., "Absorption of NPH-Insulin from Subcutaneous Tissue: A Methodological Study in Pigs," <i>Acta Pharmacol. Toxicol. (Copenh.)</i> 51:30-37, Munksgaard International Publishers Limited (1982).

EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 1 of 1

TECH CENTER 1600/2900

JUL 18 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
RT I	AL3	EP 0 462 959 B1	12/27/1991	Europe			Yes No
	AM3	EP 0 473 268 A2	03/04/1992	Europe			Yes No
	AN3	EP 0 486 959 B1	05/27/1992	Europe			Yes No
	AO3	JP 4-210928	08/03/1992	Japan			Yes No
	AP3	JP 4-230210	08/19/1992	Japan			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT I	AR	3	Gennaro, A.R., "Chapter 23: Inorganic Pharmaceutical Chemistry," in <i>Remington's Pharmaceutical Sciences</i> , 16 th Edition, Osol, A. (ed.), Mack Publishing Co., Easton, PA, pp. 343-363 (1980).
	AS	3	Ghiglione, M. et al., "How glucagon-like is glucagon-like peptide-1?" <i>Diabetologia</i> 27:599-600, Springer-Verlag (1984).
	AT	3	Gill, I.J. et al., "Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane," <i>Eur. J. Pharm. Sci.</i> 1:237-248, Elsevier Science B.V. (June 1994).


EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

JUL 18 2001

RECEIVED

Page

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1658.0020003/MAC/MBT	APPLICATION NO. 09/943,084
	APPLICANT KIM et al.	
	FILING DATE August 31, 2001	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL4	JP 4-283510	10/08/1992	Japan			Yes X No
RT	AM4	EP 0 526 862 A1	02/10/1993	Europe			Yes No
I	AN4	WO 93/18785 A1	09/30/1993	WIPO			Yes X No
	AO4	WO 93/18786 A1	09/30/1993	WIPO			Yes No
I	AP4	WO 93/19175 A1	09/30/1993	WIPO			Yes X No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	4	Heinrich, G. et al., "Pre-Proglucagon Messenger Ribonucleic Acid: Nucleotide and Encoded Amino Acid Sequences of the Rat Pancreatic Complementary Deoxyribonucleic Acid," <i>Endocrinology</i> 115:2176-2181, The Endocrine Society (1984).
I	AS	4	Hendrick, G.K. et al., "Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats," <i>Metabolism</i> 42:1-6, W.B. Saunders Company (January 1993).
I	AT	4	Hirano, K. and Yamada, H., "Studies on the Absorption of Practically Water-Insoluble Drugs following Injection VIII: Comparison of the Subcutaneous Absorption Rates from Aqueous Suspensions in the Mouse, Rat and Rabbit," <i>J. Pharm. Sci.</i> 72:608-612, American Pharmaceutical Association (1983).

EXAMINER R. Teller	DATE CONSIDERED 9/22/03
-----------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
RT	AL5	WO 93/25579 A1	12/23/1993	WIPO			Yes No
I	AM5	EP 0 619 322 A2	10/12/1994	Europe			Yes No
	AN5	WO 95/05848 A1	03/02/1995	WIPO			Yes No
	AO5	WO 95/07098 A1	03/16/1995	WIPO			Yes No
I	AP5	WO 95/17510 A1	06/29/1995	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	5	Holst, J.J. et al., "Truncated glucagon-like peptide-I, an insulin-releasing hormone from the distal gut," <i>FEBS Lett.</i> 211:169-174, Federation of European Biochemical Societies and Elsevier Science Publishers B.V. (Biomedical Division) (1987).
I	AS	5	Kreymann, B. et al., "Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man," <i>Lancet</i> 2:1300-1304, The Lancet Publishing Group (1987).
✓	AT	5	Krówczyński, L., "Technologia postaci leków (technologic galenowa)," Kierownik Katedry Farmacji Stosowanej AM w Krakowie, Warszawa, pp. 220, 463-464, 490 and 502 (1969).


EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
RT 	AL6	WO 95/31214 A1	11/23/1995	WIPO			Yes No
	AM6	EP 0 658 568 A1	06/21/1995	Europe			Yes No
	AN6	WO 96/20005 A1	07/04/1996	WIPO			Yes No
	AO6	EP 0 733 644 A1	09/25/1996	Europe			Yes No
	AP6	FR 2 732 894	10/18/1996	France			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT 	AR	6	Lacy, P.E. and Kostianovsky, M., "Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas," <i>Diabetes</i> 16:35-39, The American Diabetes Association (1967).
	AS	6	Lahey, J.R.T. et al., "Dietary Lipid Content influences the Clinical and Intestinal Adaptive Responses to Islet Transplantation in Diabetic Rats," <i>Diabetes Res.</i> 19:149-164, Tevot-Kimpton Publications (1992).
	AT	6	Lehninger, A.L. et al., "Biochemistry," Worth Publishing, New York, NY, p. 62 (1975).


EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL7	DE 195 30 865 A1	02/27/1997	Germany			Yes <input checked="" type="radio"/> No
RT	AM7	WO 97/07814	03/06/1997	WIPO			Yes <input checked="" type="radio"/> No
	AN7						Yes <input checked="" type="radio"/> No
	AO7						Yes <input checked="" type="radio"/> No
	AP7						Yes <input checked="" type="radio"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	1	Lopez, L.C. et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," <i>Proc. Natl. Acad. Sci. USA</i> 80:5485-5489, The National Academy of Sciences of the U.S.A. (1983).
	AS	1	Mosjov, S., "Structural requirements for biological activity of glucagon-like peptide-I," <i>Int. J. Peptide Protein Res.</i> 40:333-343, Munksgaard International Publishers Ltd. (September/October 1992).
	AT	1	Nara, E. et al., "A new method for assessment of drug absorption from muscle: application of a local perfusion system," <i>J. Pharm. Pharmacol.</i> 43:272-274, Pharmaceutical Press (1991).

EXAMINER

R. T. [Signature]

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL8						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	8	Seshiah, V. et al., "Effect of Bed Time Intermediate Acting Insulin in NIDDM Subjects Refractory to a Combination of Sulphonylureas and Biguanides," JAPI 40:666-668, The Association of Physicians of India (October 1992).
I	AS	8	Supersaxo, A. et al., "Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration," Pharm. Res. 7:167-169, Plenum Publishing Corporation (1990).
I	AT	8	Suzuki, S. et al., "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas," Endocrinology 125:3109-3114, The Endocrine Society (1989).

EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1500/2900

JUL 18 2002

RECEIVED

Page 9 of 10

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1658.0020003/MAC/MBT	APPLICATION NO. 09/943,084
	APPLICANT KIM et al.	
	FILING DATE August 31, 2001	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
RT	AR	2	Conn's Current Therapy, Rakel, R.E. (ed.), W.B. Saunders Company, Philadelphia, p. 483 (1989).
	AS	2	Dorland's Illustrated Medical Dictionary, Edition 28, W.B. Saunders Company, Philadelphia, p. 1613 (September 1994).
	AT	2	Roget's International Thesaurus, Third Edition, Thomas Y. Crowell Company, Inc., New York, pp. 36 and 769 (1962).

EXAMINER R. Teller	DATE CONSIDERED 9/22/03
-----------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 10 of 10

TECH CENTER 1600/2900

JUL 18 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1658.0020003/MAC/MBTAPPLICATION NO.
09/943,084APPLICANT
KIM et al.FILING DATE
August 31, 2001GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RT	AR	10	Remington's Pharmaceutical Sciences, 16 th Edition, Osol, A. (ed.), Mack Printing Company, Easton, PA, pp. 1448, 1450, 1451, 1453, 1467 and 1555 (1980).
I	AS	10	Dialog File 351, Derwent World Patent Index Accession No. 10982383, Abstract for FR 2 732 894 A1.
I	AT	10	Dialog File 351, Derwent World Patent Index Accession No. 11168515, Abstract for DE 19530865 A1.

EXAMINER

R. Teller

DATE CONSIDERED

9/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.